Related Experiment Video
Updated: May 27, 2026
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
[Issues around diffuse glioma]
1Daniel den Hoed Oncologisch Centrum, Erasmus MC, Afd. Neurologie/Neuro-oncologie, the Netherlands. m.vandenbent@erasmusmc.nl
Abstract:
Progress in treating diffuse gliomas remains limited and is principally concerned with the confirmation that cystostatics as nitrosureum derivatives and temozolomide play a role in the treatment of these tumours. At molecular level, diffuse gliomas are a heterogeneous group of tumours. This seems to be an important explanation of why so far no important breakthrough in the treatment of these tumours has been achieved. It is thought that abnormal activation of various molecular signal systems working in parallel in the tumour cell are an important cause of the absence of efficacy of the targeted agents; the inhibition of only one target appears inadequate.
Insights
Treating diffuse gliomas is challenging due to tumor heterogeneity. Targeting single molecular pathways is insufficient for effective treatment, hindering breakthroughs in diffuse glioma therapy.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer research
Background:
- Diffuse gliomas are complex brain tumors with limited treatment progress.
- Current treatments like nitrosourea derivatives and temozolomide have a confirmed role but limited efficacy.
- Tumor molecular heterogeneity is a significant barrier to effective therapeutic strategies.
Purpose of the Study:
- To explore the molecular basis of diffuse glioma treatment resistance.
- To understand why targeting single molecular pathways has failed to yield significant breakthroughs.
- To investigate the role of parallel molecular signaling in treatment inadequacy.
Main Methods:
- Review of current treatment modalities for diffuse gliomas.
- Analysis of molecular characteristics contributing to tumor heterogeneity.
- Examination of signaling pathway activation in glioma cells.
Main Results:
- Diffuse gliomas exhibit significant molecular heterogeneity.
- Abnormal activation of parallel molecular signal systems is observed.
- Inhibition of single molecular targets is inadequate for therapeutic efficacy.
Conclusions:
- Molecular heterogeneity is a key factor limiting diffuse glioma treatment success.
- Targeted therapies need to address multiple parallel pathways for efficacy.
- Further research into complex signaling networks is crucial for advancing diffuse glioma treatment.
